Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index (AMEX:RSY)
Historical Stock Chart
From Jul 2019 to Jul 2024
Recom Managed Systems (AMEX:RSY) announced that it has
completed development of a prototype device to be utilized for
noise-reduction purposes during intracardiac electrogram recordings.
The initial test of the device, which was successful, recently
occurred at the Electrophysiology Laboratories at Cleveland Clinic
Heart Center. Andrea Natale, M.D., Co-Section Head of Pacing and
Electrophysiology at The Cleveland Clinic Department of Cardiovascular
Medicine, commented: "I am excited to work together with Dr. Drakulic
on this important project."
Dr. Budimir S. Drakulic, the inventor of the company's
technologies and its Chief Technology Officer, stated: "We are very
excited to see different clinical applications being developed from
our patented signal-amplification technology. From the Company's
inception, our vision was to expand applications of our technology
from ECG signal recordings in ambulatory settings into environments of
electrophysiology and catheterization laboratories. I very much look
forward to the upcoming clinical studies that will be conducted at The
Cleveland Clinic, a prestigious medical institution that has long been
viewed as the foremost heart center in America. Dr. Andrea Natale, who
has pioneered some of the present catheter-based cures for atrial
fibrillation, has been a very important member of our Medical Advisory
board, and I am enthusiastic about our future work together. With our
new management team, the commercialization of our technologies will
undoubtedly be put to the highest and best possible use for patients."
About Recom Managed Systems, Inc.
Recom Managed Systems, Inc. is an emerging life-sciences company
focused on the monitoring and detection of disease through continuous
biomedical signal monitoring. Recom Managed Systems, Inc. uses its
patented signal technology to design and develop medical devices that
simplify and reduce the costs of diagnostic testing and patient
monitoring in an ambulatory setting. With its patented
signal-technology platform, Recom brings clinical-quality
physiological signal monitoring to the ambulatory setting.
Recom's first product, the Model 100 Heart Monitor, is an
ambulatory patient heart monitor that uses patented signal-processing
technology to record a clinical-quality ECG signal in the presence of
interference generated by the patient's body movements and ambient
environment. The Model 100 has received 510(k) clearance from the Food
and Drug Administration.
Recom Managed Systems, Inc. is traded on the American Stock
Exchange under the symbol RSY. More information is located at
http://www.recom-systems.com
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are
"forward-looking" statements. Forward-looking statements involve known
and unknown risks, which may cause Recom's actual results in the
future to differ materially from expected results. Factors which could
cause or contribute to such differences include, but are not limited
to, failure to complete the development and introduction of new
products or services, failure to obtain federal or state regulatory
approvals governing medical devices, monitoring and other related
services or products, inability to obtain physician, patient or
insurance acceptance of Recom's products or services, adverse
equity-market conditions and declines in the value of Recom's common
stock, and the unavailability of financing to complete management's
plans and objectives. These risks are qualified in their entirety by
cautionary language and risk factors set forth and to be further
described in Recom's filings with the Securities and Exchange
Commission.